Europe is facing a systemic crisis in its life sciences sector, caught in a geopolitical pincer movement between the aggressive trade policies of the United States and a rapid technological ascent in Asia. Once the epicenter of global pharmaceutical research, the continent is seeing a steady exodus of capital and innovation, leaving its healthcare systems vulnerable to delays in accessing critical recent medicines.
The pressure is mounting as President Donald Trump implements trade and drug-pricing strategies designed to prioritize American interests. From steep tariffs on branded drugs to “most-favored-nation” pricing—a policy that would peg U.S. Drug prices to the lowest price paid by another comparable country—Washington is leveraging the world’s most profitable healthcare market to force global price concessions.
While the U.S. Tightens its grip, China has transitioned from a manufacturing hub to an innovation powerhouse. Chinese-developed molecules, which accounted for only 4% of the global pipeline a decade ago, now represent nearly a third, according to data from ING. This shift is fundamentally altering where global pharma giants choose to plant their next “blockbuster” seeds.
The stakes extend beyond corporate balance sheets. Given that pharmaceutical exports are a cornerstone of the European economy, the decline in competitiveness threatens a massive trade vacuum. According to Nathalie Moll, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA), without the pharma sector, Europe would face a trade shortfall of 88 billion euros ($103 billion) rather than its current 130 billion euro surplus.
Boxes of medication are seen on the shelves of the Keencare pharmacy, a member of the Green Light Group, on September 19, 2024 in London, England.
Leon Neal | Getty Images News | Getty Images
The Erosion of the European Laboratory
The decline of Europe’s dominance in research and development (R&. D) has been a sluggish burn that is now accelerating. In 1990, nearly half of all global R&D took place within Europe, while the U.S. Held about a third. Today, those positions have flipped: the U.S. Share has surged to 55%, while Europe’s has plummeted to 26%, per ING research.
This migration is driven by structural frictions that have long plagued the European Union. While the U.S. Boasts consolidated biotech ecosystems in Boston and the Bay Area, Europe remains a fragmented patchwork of 27 different regulatory environments. This lack of cohesion creates a stifling hurdle for startups and established firms alike, with EU biotech companies receiving five to ten times less venture capital than their American counterparts.
The United Kingdom, despite its academic prestige, has served as a warning sign. Major players including AstraZeneca, Eli Lilly and Merck (known as MSD in Europe) have recently paused or scrapped planned investments in the U.K., citing a challenging life sciences environment.
| Region | R&D Share (1990) | R&D Share (Current) | Pharma Spend (% of GDP) |
|---|---|---|---|
| United States | ~33% | 55% | 2% |
| European Union | ~50% | 26% | 1% |
| China | Low | Rising | 1.8% |
Trump’s Trade Volatility and the Pricing Dilemma
The current administration in Washington has introduced a new layer of urgency through aggressive fiscal levers. Recently, the U.S. Imposed tariffs of up to 100% on certain branded drugs, targeting companies that have not reached agreements with the president to lower prices for American consumers.
However, the most disruptive threat is the “most-favored-nation” pricing model. This policy forces pharmaceutical companies into a precarious strategic choice: they must either delay launching a new drug in Europe to avoid setting a low price floor that the U.S. Would then demand, or adopt a single global price that may be prohibitively expensive for many European markets.
This dynamic creates a “value vs. Volume” calculation. For high-value specialty drugs, companies are increasingly likely to postpone European launches. So patients in Europe may wait years longer for life-saving treatments that are already available in the U.S., further decoupling the two markets.
“We need to increase spending and eradicate government clawbacks and taxes – these policies are critical to keeping companies in the EU and improving access.” — Nathalie Moll, EFPIA Director General
China’s Biotech Leap and the Global Pivot
While Europe struggles with regulation, China has aggressively scaled its biotech capabilities. The country is no longer just a source of generic chemicals; it is now a primary destination for early-stage science and “blockbuster” discovery. A recent report from PitchBook suggests that China’s biopharma advantage is likely to persist despite geopolitical friction, fueled by targeted fundraising and differentiated science.
Research from Bocconi University corroborates this trend, noting that China has emerged as the largest net recipient of foreign R&D worldwide. For global pharma companies, the attraction is simple: China offers a combination of high-speed innovation and a massive, growing patient population, contrasting sharply with the stagnant spending and regulatory hurdles found in the EU.
Can Europe Recover Its Edge?
There are emerging signs that the EU is attempting to diagnose and treat its own competitiveness gap. The proposed Biotech Act aims to streamline regulations and fast-track clinical trials, while the Critical Medicines Act seeks to secure supply chains that were exposed as fragile during the Covid-19 pandemic.
Some member states are finding success through targeted intervention. Spain, for instance, has become an attractive hub for clinical research by offering specific government support. Potential budget cuts to the U.S. National Institutes of Health (NIH) and stricter visa rules in the U.S. Could provide a window for Europe to attract top-tier talent in fields like mRNA research.
However, the gap in spending remains a primary obstacle. EU spending on medicines has remained largely flat for two decades, while the U.S. And China continue to invest more aggressively as a percentage of their GDP.
Disclaimer: This article is for informational purposes only and does not constitute financial, investment, or medical advice.
The next critical checkpoint for the industry will be the implementation phase of the EU’s Biotech Act and the potential for further U.S. Tariff adjustments as trade negotiations continue throughout the year.
We want to hear from you. How should Europe balance drug affordability with the need to keep innovation on the continent? Share your thoughts in the comments below.
